Celltrion Anticipates the Launch of Insulin Pen Biosimilar by 2025

 Celltrion Anticipates the Launch of Insulin Pen Biosimilar by 2025

Celltrion Anticipates the Launch of Insulin Pen Biosimilar by 2025

Shots:

  • Celltrion in collaboration with Poonglim Pharmatech will accelerate the development of its insulin pen biosimilar. The company will initiate the development of the insulin biosimilar in 2020 with an aim to commercially launch the product in 2025. Companies plans to develop a pen-type injection that can be administered up to 80 units at a time in an automatic injection method considering patient convenience
  • The two companies were selected for the national project where Celltrion leads development and clinical part of insulin biosimilar while Poonglim develops an Auto Pre-Filled Pen Type Injector. The national project worth 4B won for 4yrs., out of which 3B won is supported by the government
  • The National Project Evaluation Committee selected the two companies by evaluating the R&D plans, submitted by companies and the project performance and capabilities. Through the implementation of the project, when the’ Localization No. 1′ product that combines quality and cost competitiveness is released in the global insulin pen-type injection market, which has been monopolized by multinational pharmaceutical companies, it received a high score that it can lower the dependence on imports for the preparation

Click here ­to­ read full press release/ article | Ref: Celltrion | Image: Celltrion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post